Skip to Main Content

Paper Details

Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.
PLoS One
15
2021
ALK, ALUNBRIG, Brigatinib, EphA2, FAK1, Fer, NF2, NF2 deficient, NF2 deficient xenograft meningiomas, NF2 schwannomas, NF2 tumor, NF2 tumor suppressor gene, NF2-deficient meningioma, Neurofibromatosis Type 2, autosomal dominant genetic syndrome, brigatinib, focal adhesion kinase 1, malignancies, meningioma, meningioma nor, meningiomas, murine, neither, schwannoma, schwannoma cells, schwannomas, tumor, tumors, tyrosine, tyrosine kinases
Author NameAffiliation
Marc FerrerDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health
Xiaohu ZhangDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health
Rajarshi GuhaDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health
Rajarshi GuhaDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health
Craig J ThomasDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health
David JonesIndiana University
Stephen J HaggartyMassachusetts General Hospital and Department of Neurology, Center for Genomic Medicine, Harvard Medical School
Salvatore La RosaChildren's Tumor Foundation
Anat Stemmer-RachamimovMassachusetts General Hospital and Harvard Medical School
James F GusellaCenter for Genomic Medicine, Massachusetts General Hospital and Department of Genetics, Blavatnik Institute, Harvard Medical School
Justin Guinney
Justin Guinney
Gary L JohnsonUniversity of North Carolina School of Medicine
Jaishri O BlakeleyJohns Hopkins University School of Medicine
  • 1 - 14

Datasets

Release 1.2